CardioSource WorldNews | Page 45

COMMITTED TO PATIENT SAFETY... XARELTO® establishing real-world outcomes IMPORTANT SAFETY INFORMATION (cont’d) Nursing Mothers: It is not known if rivaroxaban is excreted in human milk. Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Females of Reproductive Potential: Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. ADVERSE REACTIONS IN CLINICAL STUDIES The most common adverse reactions with XARELTO® were bleeding complications. Please see accompanying Brief Summary of full Prescribing Information, including Boxed WARNINGS, or visit www.XareltoHCP.com/PI. 052840-160508 USE IN SPECIFIC POPULATIONS (cont’d) OVERDOSAGE S:13 in T:14 in B:14.25 in Discontinue XARELTO® and initiate appropriate therapy if bleeding complications associated with overdosage occur. A specific antidote for rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of XARELTO® overdose may be considered. Due to the high plasma protein binding, riva